Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230603 | 0.90 | KMT2A (0.56) | KMT2AMEN1TSHRHTTLMNA | |
| SCHEMBL6646760 | 0.89 | KMT2A (0.67) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL5875796 | 0.89 | MEN1 (0.60) | KMT2AMEN1TSHRHTTLMNA | |
| Hydrochloric Acid SCHEMBL2290641 | 0.89 | KMT2A (0.56) | KMT2AMEN1TSHRHTTLMNA | |
| Acetic Acid SCHEMBL1232023 | 0.88 | KMT2A (0.55) | KMT2AMEN1TSHRHTTLMNA | |
| SCHEMBL6880703 | 0.88 | KMT2A (0.55) | KMT2AMEN1TSHRHTTLMNA | |
| SCHEMBL13173304 | 0.86 | KMT2A (0.57) | KMT2AMEN1TSHRHTTLMNA | |
| SCHEMBL1668350 | 0.84 | KMT2A (0.56) | KMT2AMEN1TSHRHTTLMNA | |
| SCHEMBL13173290 | 0.83 | PKM (0.57) | KMT2AMEN1TSHRHTTALDH1A1 | |
| SCHEMBL6196273 | 0.81 | KMT2A (0.56) | KMT2ATSHRHTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410098-B2 | N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-OXO-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2013-04-02 | — | — | US | disclosed |
| US-8410098-B2 | N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-OXO-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2013-04-02 | — | — | US | disclosed |
| EP-2228370-B1 | N-{1-[3-(2-ETHOXY-5-(4-ETHYLPIPERAZINYL)BENZENESULFONYL)-4,5-DIHYDRO-5-OXO-1,2,4-TRIAZIN-6-YL]ETHYL}BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-05-23 | — | — | EP | disclosed |
| EP-2228370-B1 | N-{1-[3-(2-ETHOXY-5-(4-ETHYLPIPERAZINYL)BENZENESULFONYL)-4,5-DIHYDRO-5-OXO-1,2,4-TRIAZIN-6-YL]ETHYL}BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-05-23 | — | — | EP | disclosed |
| US-20110190495-A1 | N-BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2011-08-04 | — | — | US | disclosed |
| US-20110190495-A1 | N-BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2011-08-04 | — | — | US | disclosed |
| EP-2228370-A1 | N-{1-Ý3-(2-ETHOXY-5-(4-ETHYLPIPERAZINYL)BENZENESULFONYL)-4,5-DIHYDRO-5-OXO-1,2,4-TRIAZIN-6-YL¨ETHYL}BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF | Topharman Shanghai Co., Ltd. (CN) | 2010-09-15 | — | — | EP | disclosed |
| EP-2228370-A1 | N-{1-Ý3-(2-ETHOXY-5-(4-ETHYLPIPERAZINYL)BENZENESULFONYL)-4,5-DIHYDRO-5-OXO-1,2,4-TRIAZIN-6-YL¨ETHYL}BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF | Topharman Shanghai Co., Ltd. (CN) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190495-A1 | N-BUTYRAMIDE, THE PREPARATION METHOD AND USE THEREOF | CYP3A5, PDE3A, PDE5A | KMT2A 3337/4885MEN1 4553/4885TSHR 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.